Description
Prostamax is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Pro (KEDP), developed by Professor Vladimir Khavinson from prostate tissue extract. It is the prostate-targeted member of the Khavinson bioregulator series. Like other bioregulators in this class, Prostamax enters cell nuclei and modulates gene expression through direct peptide-DNA interaction. Its primary research context is prostatic tissue biology — chromatin decondensation in prostate cells, androgen receptor signaling pathways, and inflammatory gene regulation in glandular tissue models. A secondary research finding places it in lymphocyte chromatin biology, documented by Meskhi et al. in a specialty research peptide context that parallels Livagen’s dual-tissue profile.
Chemical Information
- Chemical Name: Prostamax (Khavinson prostate tissue-derived tripeptide bioregulator)
- Also Known As: Prostamax peptide complex
- Compound Class: Short-chain synthetic tripeptide; tissue-specific epigenetic bioregulator (Khavinson series)
- Sequence: Not established in public literature
- Molecular Formula: Not established in public literature
- Molecular Weight: Not established in public literature (consistent with the broader Khavinson class of low molecular weight peptides, <10,000 Da)
- CAS Number: Not established in public literature
Applications
- Prostate tissue-specific gene regulation research. Prostamax is modeled on prostate tissue and is proposed to act via direct peptide-DNA interaction within prostate cell nuclei, modulating expression of genes involved in prostate tissue regulation. It shares this mechanism shared with other tissue-targeted Khavinson bioregulators such as Livagen (hepatocytes) and Cardiogen (cardiomyocytes)
- Comparative organ-specific bioregulator research. Published Khavinson-network literature on tissue-specific bioregulators has examined organ-directed gene programs in matched tissue systems; Prostamax is studied within this framework for prostate-directed effects
- Cross-tissue bioregulator specificity research. Studies suggest that it shares its intranuclear DNA-interaction mechanism with other short-chain Khavinson peptides. As such, researches use it alongside tissue-matched and mismatched bioregulators to test whether reported gene-regulatory effects are tissue-restricted or tissue-general
- Note on evidence base: Published data on Prostamax is mostly in Russian-language and Khavinson-network literature and are largely preclinical; independent Western replication is limited
Storage and Handling
Store lyophilized powder under refrigeration (2-8C), protected from heat, light, and moisture. As a short-chain peptide, Prostamax is susceptible to proteolytic degradation once reconstituted. Reconstitute immediately before use, keep reconstituted solution refrigerated, and avoid repeated freeze-thaw cycles.
Compliance Notice
Prostamax is for laboratory research use only. They are not for human or veterinary use and carry no therapeutic, diagnostic, or clinical indication. FDA has not evaluated this product. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.
